First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials
暂无分享,去创建一个
Z. Ren | Xin Yin | B. Quan | Miao Li | Shenxin Lu | Wenfeng Liu | Rongxin Chen | B. Tang
[1] F. Chen,et al. Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Jinhai Wang,et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. , 2021, The Lancet. Oncology.
[3] R. Sacco,et al. Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma , 2020, Vaccines.
[4] M. Kudo,et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib , 2020, JAMA oncology.
[5] M. Iannacone,et al. Immune surveillance of the liver by T cells , 2020, Science Immunology.
[6] W. Gu,et al. Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysis , 2020, The Journal of international medical research.
[7] Yan Zhao,et al. Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy. , 2020, Biochimica et biophysica acta. Reviews on cancer.
[8] M. Lee,et al. Detection of Hepatocellular Carcinoma in Contrast-Enhanced Magnetic Resonance Imaging Using Deep Learning Classifier: A Multi-Center Retrospective Study , 2020, Scientific Reports.
[9] M. Lee,et al. Detection of Hepatocellular Carcinoma in Contrast-Enhanced Magnetic Resonance Imaging Using Deep Learning Classifier: A Multi-Center Retrospective Study , 2020, Scientific Reports.
[10] Yulei N. Wang,et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.
[11] L. Woon,et al. Nivolumab for the treatment of hepatocellular carcinoma. , 2020 .
[12] W. Dai,et al. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis , 2020, Journal of Experimental & Clinical Cancer Research.
[13] W. Dai,et al. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis , 2020, Journal of Experimental & Clinical Cancer Research.
[14] R. Sacco,et al. Efficacy of Regorafenib in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis , 2019, Cancers.
[15] N. Gray,et al. Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU‐285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies , 2019, British journal of haematology.
[16] Zhonglin Hao,et al. Lenvatinib in Management of Solid Tumors. , 2019, The oncologist.
[17] M. Kudo,et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) , 2019, Annals of Oncology.
[18] K. Syrigos,et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. , 2019, The New England journal of medicine.
[19] L. Schwartz,et al. Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. , 2019, JAMA oncology.
[20] Zaina T. Al-Salama,et al. Lenvatinib: A Review in Hepatocellular Carcinoma , 2019, Drugs.
[21] M. Ychou,et al. Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial , 2019, British Journal of Cancer.
[22] Li Jin,et al. The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. , 2019, Journal of hepatology.
[23] Sheridan M. Hoy. Sintilimab: First Global Approval , 2019, Drugs.
[24] M. Cabanillas,et al. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. , 2019, Seminars in oncology.
[25] M. Kudo. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update , 2018, Liver Cancer.
[26] T. Zheng,et al. Role of ferroptosis in hepatocellular carcinoma , 2018, Journal of Cancer Research and Clinical Oncology.
[27] M. Kudo,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.
[28] Bohuslav Melichar,et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.
[29] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[30] M. Kudo,et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial , 2017, The Lancet.
[31] G. Keating. Sorafenib: A Review in Hepatocellular Carcinoma , 2017, Targeted Oncology.
[32] Myung Ah Lee,et al. Resminostat and sorafenib combination therapy for advanced hepatocellular carcinoma in patients previously untreated with systemic chemotherapy. , 2017 .
[33] Masatoshi Kudo,et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.
[34] R. Addeo,et al. Hepatocellular carcinoma: Will novel targeted drugs really impact the next future? , 2016, World journal of gastroenterology.
[35] A. Luciani,et al. Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features , 2016, Hepatology.
[36] G. Tiegs,et al. Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells , 2016, Cellular & Molecular Immunology.
[37] A. Taketomi. Clinical trials of antiangiogenic therapy for hepatocellular carcinoma , 2016, International Journal of Clinical Oncology.
[38] M. Kudo,et al. Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study. , 2015, Journal of hepatology.
[39] J. Bruix,et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] Ying Cheng,et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] Gerta Rücker,et al. Reduce dimension or reduce weights? Comparing two approaches to multi‐arm studies in network meta‐analysis , 2014, Statistics in medicine.
[42] L. Jeng,et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] M. Kudo,et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] J. Prieto,et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. , 2013, Journal of hepatology.
[45] V. Nitti,et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. , 2013, The Journal of urology.
[46] Gordon H Guyatt,et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. , 2013, Journal of clinical epidemiology.
[47] P. Gargiulo,et al. A case of GH deficiency and beta-thalassemia. , 2012, Minerva endocrinologica.
[48] J. Sterne,et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.
[49] M. Joerger,et al. Antiangiogenic Drugs in Oncology: A Focus on Drug Safety and the Elderly – A Mini-Review , 2009, Gerontology.
[50] Zhuang Liu,et al. Drug delivery with carbon nanotubes for in vivo cancer treatment. , 2008, Cancer research.
[51] Dieter Häussinger,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[52] A. Hackshaw,et al. A phase III randomised, double blind, placebo controlled trial of gemcitabine/carboplatin with or without thalidomide in advanced non-small cell lung cancer (NSCLC) , 2007 .
[53] G. Guyatt,et al. Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.
[54] A. Pillai,et al. Goals and targets for personalized therapy for HCC , 2019, Hepatology International.
[55] J. Wolchok,et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[56] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.